Additionally, we have identified STAT5a as critical mediator of the hTERT gene expression in BCR-ABL positive CML cells, suggesting that targeting STAT5a may be a promising therapeutic strategy for BCR-ABL positive CML patients. This evidence concerns the gene STAT5A and chronic myelogenous leukemia, BCR-ABL1 positive.